Nymox 2005 product sales increase 32%

By Lisa Kerner

Erie, Pa., March 15 - Nymox Pharmaceutical Corp.'s product sales for the year ended Dec. 31 increased by 32% to $424,506, compared with $321,895 for 2004.

The company reported a net loss of $3,584,528, or $0.14 per share, down slightly from the $3,745,625, or $0.15 per share, for 2004.

"The company had a highly productive year in which many solid milestones were made, while our burn rate was again minimal by industry standards," chief executive officer and president Paul Averback said in a company news release.

Nymox, a biopharmaceutical company based in Hasbrouck Heights, N.J., is developing products for the treatment of benign prostatic hyperplasia, Alzheimer's disease and E. coli.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.